GR Premiers GRMN Corolla

Toyota City, Japan, June 4, 2026 - (JCN Newswire via SeaPRwire.com) - GAZOO Racing (GR) held the world premiere today of the GRMN Corolla―the ultimate GR Corolla, engineered to deliver a confident, full-throttle experience on Germany's Nürburgring racetrack, the starting point for both GR, which is committed to building ever-better…

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta…

Newborn Town Cancels Over 5.17 Million Repurchased Shares, Cumulative Amount Exceeds HK$45 Million

EQS via SeaPRwire.com / 04/06/2026 / 19:30 UTC+8 [Hong Kong – 4 June 2026] Newborn Town Inc., a leading global social entertainment company (Newborn Town or the company, stock code: 09911.HK) is pleased to announced that it has cancelled a total of 5,174,000 shares repurchased between 27 April  and 29 May 2026, representing an aggregate repurchase consideration…

Island States Ocean Summit Opens in Tokyo

TOKYO, June 4, 2026 - (JCN Newswire via SeaPRwire.com) - The Nippon Foundation, in partnership with the Ministry of Foreign Affairs of Japan and the Intergovernmental Oceanographic Commission (IOC) of UNESCO, officially opened the Island States Ocean Summit on June 3, 2026 at Hotel New Otani Tokyo. His Majesty the Emperor…

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s…